Simulations Plus Embarks On Collaboration With Northeastern University And The TIM Company Through New FDA Grant
Portfolio Pulse from Benzinga Newsdesk
Simulations Plus, Inc. (NASDAQ:SLP) has been awarded a new FDA grant in collaboration with Northeastern University and The TIM Company. The partnership will focus on integrating experimental data and PBPK modeling to expedite the development of generic oral modified-release (MR) drug products. The project involves generating in vitro data and using PBPK/PBBM models to predict clinical pharmacokinetics of MR formulations. The collaboration aims to streamline drug development and enhance healthcare solutions, with FDA staff actively participating.
January 09, 2024 | 1:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Simulations Plus, Inc. is part of a collaboration awarded an FDA grant to improve the development of generic oral MR drugs, potentially enhancing the company's modeling and simulation solutions.
The FDA grant and collaboration with Northeastern University and The TIM Company are likely to enhance Simulations Plus's reputation and capabilities in drug development modeling. This could lead to increased demand for their services and potentially higher revenues in the short term, positively impacting the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90